Author

A. B. Cortot

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Vinchent· 2 shared D. Tulasne· 2 shared A. Arabo· 1 shared A. Bardelli· 1 shared A. Guernet· 1 shared A. Laratte· 1 shared B. C. Cho· 1 shared C. Berard· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Vinchent

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

C. M. Guerin, A. Vinchent, M. Fernandes, I. Damour, A. Laratte, R. Tellier, G. O. Estevam, J.-P. Meneboo, C. Villenet, C. Descarpentries, J. S. Fraser, M. Figeac, A. B. Cortot, E. Rouleau, D. Tulasne

This paper identifies N-lobe MET mutations in HPRCC that require ligand stimulation for activation, unlike kinase domain mutations, and shows their sensitivity to MET inhibitors.

bioRxiv · Nov 3, 2023Cancer Biology

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells

L. Brunet, D. Alexandre, J. Lee, M. d. M. Blanquer-Rossello, A. Guernet, H. Chhouri, Z. Kherrouche, A. Arabo, S. Yao, D. Godefroy, J. Dehedin, J.-R. Li, C. Duparc, P. Jamme, A. Vinchent, , L. Grumolato

This study shows that sorafenib can prolong lung cancer response to EGFR inhibitors by targeting resistant cells' selective advantage.

bioRxiv · Jun 19, 2023Cancer Biology